71 related articles for article (PubMed ID: 38446675)
1. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
[TBL] [Abstract][Full Text] [Related]
2. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
[TBL] [Abstract][Full Text] [Related]
3. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
4. Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
Rosenberg JE; Mamtani R; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Sridhar SS; Pappot H; Gurney H; Bedke J; van der Heijden MS; Galli L; Keam B; Masumori N; Meran J; O'Donnell PH; Park SH; Grande E; Sengeløv L; Uemura H; Skaltsa K; Campbell M; Matsangou M; Wu C; Hepp Z; McKay C; Powles T; Petrylak DP
Eur Urol; 2024 Jun; 85(6):574-585. PubMed ID: 38418343
[TBL] [Abstract][Full Text] [Related]
5. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract][Full Text] [Related]
7. Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions.
Endo Y; Akatsuka J; Takeda H; Hasegawa H; Yanagi M; Toyama Y; Mikami H; Shibasaki M; Kimura G; Kondo Y
Curr Oncol; 2024 Jan; 31(2):759-768. PubMed ID: 38392050
[TBL] [Abstract][Full Text] [Related]
8. Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract.
Chan KH; Shu T; Al Shaarani M; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241257333. PubMed ID: 38804541
[TBL] [Abstract][Full Text] [Related]
9. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; ():. PubMed ID: 38807017
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato A; Furubayashi N; Nagata Y; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
Curr Oncol; 2024 Feb; 31(2):862-871. PubMed ID: 38392058
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Sheng X; Wang L; He Z; Shi Y; Luo H; Han W; Yao X; Shi B; Liu J; Hu C; Liu Z; Guo H; Yu G; Ji Z; Ying J; Ling Y; Yu S; Hu Y; Guo J; Fang J; Zhou A; Guo J
J Clin Oncol; 2024 Apr; 42(12):1391-1402. PubMed ID: 37988648
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
13. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
Brown JR; Koshkin VS
Eur Urol Focus; 2024 May; ():. PubMed ID: 38797658
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
Hara T; Matsushita Y; Harada K; Fujimoto N; Fujisawa M; Miyake H
Int J Urol; 2024 Jun; 31(6):696-698. PubMed ID: 38424707
[No Abstract] [Full Text] [Related]
15. Refractory insulin resistance and hemophagocytic lymphohistiocytosis following enfortumab vedotin treatment: A case report.
Rossignon P; Nguyen LDK; Boegner P; Ku J; Herpain A
Mol Clin Oncol; 2024 Jun; 20(6):44. PubMed ID: 38799283
[TBL] [Abstract][Full Text] [Related]
16. A Real-World Retrospective Analysis of the Management of Advanced Urothelial Carcinoma in Canada.
Moria FA; Park CL; Eigl BJ; Macfarlane R; Pavic M; Saleh RR
Curr Oncol; 2024 Jan; 31(2):704-722. PubMed ID: 38392046
[TBL] [Abstract][Full Text] [Related]
17. Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases.
Nishio K; Higashio T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Tsuchida S; Matsuda T; Tsujino T; Nishimura K; Tokushige S; Nakamori K; Uchimoto T; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Kimura T; Ohno Y; Shiroki R; Azuma H
Oncology; 2024; 102(6):457-464. PubMed ID: 37839399
[TBL] [Abstract][Full Text] [Related]
18. Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.
Anker J; Pal SK; Kim-Schulze S; Wang H; Halperin R; Uzilov A; Imai N; Eikawa S; Saito T; Sebra R; Hahn NM; Patel M; Qi J; Xie H; Bhardwaj N; Gnjatic S; Galsky MD
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37607770
[TBL] [Abstract][Full Text] [Related]
19. SDRIFE and bullous reaction after treatment with enfortumab vedotin plus pembrolizumab: Case series.
Lluch-Galcerá JJ; Manzanares-Oliver N; Martinez-Molina M; Valdivieso L; Boada A; Segura S; Rovira R; Pujol RM; Jaka A
J Dtsch Dermatol Ges; 2024 May; ():. PubMed ID: 38778438
[No Abstract] [Full Text] [Related]
20. Is HER2 the New NECTIN4 in Advanced Urothelial Cancer?
Nally E; Young M; Wells C; Fairhead R; Baines K; Cheney-Lowe H; Jackson-Spence F; Powles T
Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38825408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
